A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. We aim to achieve this goal through Deep Cyclic Inhibition® of clinically-validated core signaling pathways such as the mitogen-activated protein kinase ("MAPK") pathway, impacting cancer cells while sparing healthy cells. Our inclusive approach differentiates us from chronically targeted precision therapies, which are generally limited by toxicity, resistance and/or application to specific mutations only. We are currently evaluating our lead product candidate, IMM-1-104, in a Phase 1/2a clinical trial in patients with advanced solid tumors including those harboring RAS or RAF mutations. IMM-1-104 is being developed as a once-daily oral deep cyclic inhibitor of the MAPK signaling pathway, specifically at the level of mitogen-activated protein kinase kinase ("MEK").
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - |
| Net Income | -62M | -53M | -51M | -34M | -17M |
| EPS | $-1.79 | $-1.88 | $-1.91 | $-2.46 | $-3.44 |
| Free Cash Flow | -50M | -49M | -45M | -31M | -15M |
| ROIC | -12266.3% | -59.0% | -46.0% | -21.5% | -35.1% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.13 | 0.11 | 0.07 | -0.12 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -64M | -58M | -52M | -34M | -17M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | -27.4% | -53.4% | -46.0% | -21.5% | - |
| Shares Outstanding | 65M | 28M | 26M | 14M | 26M |
| Metric | 2020 | 2021 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -17M | -34M | -52M | -58M | -64M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -17M | -34M | -51M | -53M | -62M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -35.1% | -21.5% | -46.0% | -59.0% | N/M |
| ROE | N/A | -21.5% | -46.0% | -53.4% | -27.4% |
| ROA | -44.3% | -20.1% | -41.3% | -47.5% | -25.9% |
| Cash Flow | |||||
| Op. Cash Flow | -15M | -31M | -44M | -49M | -50M |
| Free Cash Flow | -15M | -31M | -45M | -49M | -50M |
| Owner Earnings | -16M | -33M | -48M | -55M | -56M |
| CapEx | 53K | 61K | 742K | 343K | 28K |
| Maint. CapEx | 24K | 45K | 247K | 323K | 323K |
| Growth CapEx | 29K | 15K | 495K | 20K | 0 |
| D&A | 24K | 45K | 247K | 323K | 323K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.1M | 1.8M | 4.1M | 5.7M | 5.7M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -228M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | 228M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.12 | 0.07 | 0.11 | 0.13 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A |
| Equity | -22M | 156M | 110M | 91M | 228M |
| Total Assets | 38M | 167M | 122M | 103M | 241M |
| Total Liabilities | 2.8M | 11M | 13M | 12M | 13M |
| Intangibles | N/A | 6.7M | 6.7M | 6.7M | 6.7M |
| Retained Earnings | -26M | -59M | -110M | -163M | -163M |
| Working Capital | 35M | 147M | 101M | 81M | 81M |
| Current Assets | 38M | 152M | 109M | 89M | 89M |
| Current Liabilities | 2.3M | 5.6M | 8.1M | 7.8M | 7.8M |
| Per Share Data | |||||
| EPS | -3.44 | -2.46 | -1.91 | -1.88 | -1.79 |
| Owner EPS | -0.60 | -2.40 | -1.83 | -1.93 | -0.87 |
| Book Value | -0.85 | 11.44 | 4.15 | 3.18 | 3.53 |
| Cash Flow/Share | -0.55 | -2.26 | -1.67 | -1.72 | -0.96 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 26.4M | 13.6M | 26.4M | 28.4M | 64.6M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -3.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.5 | 1.1 | 2.4 | 1.5 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -13.6% | -38.8% | -22.2% | -14.3% |
| Market Cap | N/A | 227M | 116M | 222M | 349M |
| Avg. Price | N/A | 25.63 | 8.09 | 7.75 | 5.41 |
| Year-End Price | N/A | 16.68 | 4.37 | 7.80 | 5.41 |
Immuneering Corp passes 0 of 9 quality checks, indicating weak fundamentals.
Immuneering Corp (IMRX) has a 5-year average return on invested capital (ROIC) of -40.4%. This is below average and may indicate limited pricing power.
Immuneering Corp (IMRX) has a market capitalization of $349M. It is classified as a small-cap stock.
Immuneering Corp (IMRX) does not currently pay a regular dividend.
Immuneering Corp (IMRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Immuneering Corp (IMRX) generated $-49 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Immuneering Corp (IMRX) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
Immuneering Corp (IMRX) reported earnings per share (EPS) of $-1.88 in its most recent fiscal year.
Immuneering Corp (IMRX) has a return on equity (ROE) of -53.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Immuneering Corp (IMRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Immuneering Corp (IMRX) has a book value per share of $3.18, based on its most recent annual SEC filing.
No recent press releases.